OBI Pharma, Inc.

OBI Pharma, Inc. is a biopharmaceutical company that specializes in the development of novel therapeutic agents for unmet medical needs, particularly in the field of oncology and immunology. The company was established in 2002 and is headquartered in Taipei, Taiwan.

History[edit | edit source]

OBI Pharma, Inc. was founded by Dr. Michael Chang, a renowned scientist in the field of virology and molecular biology. The company was established with the aim of developing innovative drugs for the treatment of cancer and other serious diseases.

Research and Development[edit | edit source]

OBI Pharma, Inc. has a robust research and development program that focuses on the discovery and development of novel therapeutic agents. The company's research efforts are primarily focused on the fields of oncology and immunology.

The company's lead product, OBI-822, is a novel glycolipid antigen-based vaccine for the treatment of metastatic breast cancer. OBI-822 is currently in Phase III clinical trials and has shown promising results in early-stage studies.

In addition to OBI-822, the company has several other products in various stages of development. These include OBI-833, a glycoengineered monoclonal antibody for the treatment of non-small cell lung cancer, and OBI-888, a first-in-class glycoimmune checkpoint inhibitor for the treatment of solid tumors.

Partnerships and Collaborations[edit | edit source]

OBI Pharma, Inc. has established several strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies worldwide. These partnerships have enabled the company to accelerate the development of its pipeline products and expand its global presence.